MetaCap

Bicara Therapeutics (BCAX) vs Immix Biopharma (IMMX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immix Biopharma (IMMX) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 60.7% versus a loss of 53.2%. Immix Biopharma is the larger company by market cap ($583.3 million vs $560.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCAX-53.22%IMMX+60.74%
+249%+89%-71%
Nov 21, 20251 yearNov 20, 2026
BCAX-63.95%IMMX+274.19%
+685%+293%-100%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCAX versus IMMX key metrics
MetricBCAXIMMX
Share price$8.44$6.96
Market cap$560.31M$583.33M
1-day change-7.46%-1.14%
YTD return-49.85%+33.08%
1-year return-53.22%+60.74%
EPS (TTM)$-3.46$-0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-137.95M$-29.40M
52-week high$30.99$15.10
52-week low$7.87$3.78
Distance from 52-week high-72.77%-53.91%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+281.16%+243.82%
Average volume1.20M1.45M
Shares outstanding66.39M83.81M
Employees10321
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMX has outperformed BCAX by 114.0 percentage points over the past year.

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Immix Biopharma

IMMX stock →

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

BCAX vs IMMX FAQ

Which is bigger, Bicara Therapeutics or Immix Biopharma?

Immix Biopharma (IMMX) is larger, with a market capitalization of $583.33M compared with $560.31M for Bicara Therapeutics (BCAX).

Which stock has performed better over the past year, BCAX or IMMX?

IMMX returned +60.74% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Bicara Therapeutics and Immix Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons